Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

Nature Medicine 2026 Open access

Read full text
Authors: Richard S. Finkel, Thomas O. Crawford, E Mercuri, Charlotte J. Sumner, María del Mar García Romero, John W. Day, Jacqueline Montes, Peng Sun, B. Tichler, Angela D. Paradis, Emily Boesch, Jennifer A. Inra
+7 more Ross Littauer, Jihee Sohn, Michael I. Monine, Giulia Gambino, Richard Foster, Raechel Farewell, Stephanie Fradette
DOI: 10.1038/s41591-026-04415-5
Cited by: 1

Abstract

In the version of the article initially published, there were errors in the NfL data in Fig. 2 , Table 2 and Extended Data Fig. 4 . The original figures and table are available for comparison in the Supplementary information accompanying this amendment. In the Results, in the “Part B cohort with infantile-onset SMA: neurodegeneration” section, the text “…compared with the ENDEAR matched sham group (30% reduction)” has been corrected to “…compared with the ENDEAR matched sham group (32% reduction)”, and “nominally significant P = 0.0050” has been corrected to “nominally significant P = 0.0075”. In the “Part B cohort with later-onset SMA: neurodegeneration” section, the text “nominally significant P = 0.0495” has been corrected to “nominally significant P = 0.0047”. These corrections have been made to the HTML and PDF versions of the article.

Fields of Study & Subjects

Neurogenetic and Muscular Disorders Research Amyotrophic Lateral Sclerosis Research Hereditary Neurological Disorders

Publication details

Journal / source
Nature Medicine
Publisher
Springer Science and Business Media LLC
Volume
32
Issue
5
Pages
1936–1936
Publication date
23 April 2026
Language
EN